Uncategorized
STAT+: Can Erasca be biotech’s next big thing? We’ll see
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I wore my Tottenham Hotspur hoodie while shopping at Market Basket last Sunday. One fellow shopper laughed at me. He must have been an Arsenal fan. But another guy commiserated.
If none of this means anything to you, I’m sorry. My favorite soccer team is circling the drain and I feel sad.
The promise of a better pan-RAS inhibitor
Erasca has been described as the poor man’s Revolution Medicines. Impoverished doesn’t exactly fit, not with Erasca’s market value nearing $7 billion on the promise of a better pan-RAS inhibitor for pancreatic cancer. But RevMed’s value now tops $30 billion, so you can see why biotech investors are motivated to find the next big thing.
Whether Erasca is worthy of that description will become clearer in May when the company reports initial results from an early stage study of its drug, called ERAS-0015.
“RevMed has been a real pioneer in this space,” Erasca co-founder and CEO Jonathan Lim told me when we spoke on Tuesday. “What a day it was last week seeing their data with 13.2 months of median overall survival. It’s great for patients with pancreatic cancer.”
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I wore my Tottenham Hotspur hoodie while shopping at Market Basket last Sunday. One fellow shopper laughed at me. He must have been an Arsenal fan. But another guy commiserated.
If none of this means anything to you, I’m sorry. My favorite soccer team is circling the drain and I feel sad.
The promise of a better pan-RAS inhibitor
Erasca has been described as the poor man’s Revolution Medicines. Impoverished doesn’t exactly fit, not with Erasca’s market value nearing $7 billion on the promise of a better pan-RAS inhibitor for pancreatic cancer. But RevMed’s value now tops $30 billion, so you can see why biotech investors are motivated to find the next big thing.
Whether Erasca is worthy of that description will become clearer in May when the company reports initial results from an early stage study of its drug, called ERAS-0015.
“RevMed has been a real pioneer in this space,” Erasca co-founder and CEO Jonathan Lim told me when we spoke on Tuesday. “What a day it was last week seeing their data with 13.2 months of median overall survival. It’s great for patients with pancreatic cancer.”
Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial:
🧠 Novo’s Parkinson’s cell therapy finds a biotech home: Novo Nordisk has found a home for an early-stage …
Uncategorized
STAT+: Astellas treatment offers new hope to a devastated rare disease community
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.
Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.
Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption.
Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
New home for Novo’s Parkinson’s cell therapy; GSK turns to China for hep B drug
STAT+: Astellas treatment offers new hope to a devastated rare disease community
Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
Biotech layoffs are easing, but is the worst over?
The connection between periods and mental health
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
Disney’s live-action Aladdin finally finds its stars